Cargando…

Erythropoietin: current status.

Understanding the regulation of red blood cell production has been greatly enhanced by the cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The availability of recombinant human erythropoietin (rhEpo) for administration to patients has ushered in a new era in molec...

Descripción completa

Detalles Bibliográficos
Autor principal: Bunn, H. F.
Formato: Texto
Lenguaje:English
Publicado: Yale Journal of Biology and Medicine 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589359/
https://www.ncbi.nlm.nih.gov/pubmed/2293499
_version_ 1782161103092973568
author Bunn, H. F.
author_facet Bunn, H. F.
author_sort Bunn, H. F.
collection PubMed
description Understanding the regulation of red blood cell production has been greatly enhanced by the cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The availability of recombinant human erythropoietin (rhEpo) for administration to patients has ushered in a new era in molecular medicine. Intravenous or subcutaneous administration of rhEpo can reliably cure the anemia of chronic renal failure and may be effective in the treatment of anemias secondary to chronic inflammation, malignancy, and marrow suppression from chemotherapy. In addition, rhEpo therapy will probably play a prominent role in transfusion medicine, both in preparing patients for auto-transfusions as well as in minimizing red cell transfusion requirements in the post-operative period.
format Text
id pubmed-2589359
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Yale Journal of Biology and Medicine
record_format MEDLINE/PubMed
spelling pubmed-25893592008-11-28 Erythropoietin: current status. Bunn, H. F. Yale J Biol Med Research Article Understanding the regulation of red blood cell production has been greatly enhanced by the cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The availability of recombinant human erythropoietin (rhEpo) for administration to patients has ushered in a new era in molecular medicine. Intravenous or subcutaneous administration of rhEpo can reliably cure the anemia of chronic renal failure and may be effective in the treatment of anemias secondary to chronic inflammation, malignancy, and marrow suppression from chemotherapy. In addition, rhEpo therapy will probably play a prominent role in transfusion medicine, both in preparing patients for auto-transfusions as well as in minimizing red cell transfusion requirements in the post-operative period. Yale Journal of Biology and Medicine 1990 /pmc/articles/PMC2589359/ /pubmed/2293499 Text en
spellingShingle Research Article
Bunn, H. F.
Erythropoietin: current status.
title Erythropoietin: current status.
title_full Erythropoietin: current status.
title_fullStr Erythropoietin: current status.
title_full_unstemmed Erythropoietin: current status.
title_short Erythropoietin: current status.
title_sort erythropoietin: current status.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589359/
https://www.ncbi.nlm.nih.gov/pubmed/2293499
work_keys_str_mv AT bunnhf erythropoietincurrentstatus